胰高血糖素样肽-1与胃肠动力研究进展  

Progress in research on GLP-1 and gastrointestinal motility

作　　者：徐昕[1] 王邦茂[1] XU Xin;WANG Bang-mao(Department of Gastroenterology,General Hospital of Tianjin Medical University,Tianjin 300052,China.)

机构地区：[1]天津医科大学总医院消化科

出　　处：《中国处方药》2020年第1期22-24,共3页Journal of China Prescription Drug

基　　金：国家自然科学基金项目（81900487）

摘　　要：胰高血糖素样肽-1(GLP-1)为一种重要的肠促胰岛素,可通过多种机制发挥重要的降血糖作用,因而在2型糖尿病(T2DM)的治疗中备受重视。另外,GLP-1亦发挥重要的心血管保护、肾脏保护、调节脂代谢,及改善胰岛素敏感性等功能。值得注意的是,GLP-1对胃排空及胃肠动力亦具有一定的抑制作用。因此,本文就GLP-1与胃肠动力关系的研究进展做一综述,旨在为GLP-1在胃肠动力障碍性疾病的发病机制及治疗中的潜在价值开辟新的视角。Glucagon-like peptide-1(GLP-1),a member of the glucagon-like peptide family,plays an important role in the regulation of glucose,and has received much attention in the treatment of type 2 diabetes mellitus(T2DM).In addition,GLP-1 also plays a crucial part in cardiovascular protection,kidney protection,lipid metabolism regulation,and the improvement of insulin sensitivity.Moreover,it is noteworthy that GLP-1 has an effect on the inhibition of gastric emptying and gastrointestinal motility.Therefore,the progress and relationship between GLP-1 and gastrointestinal motility is discussed in this review.The aim is to open up a new perspective on the potential value of GLP-1 in the pathogenesis and treatment of gastrointestinal motility disorders.

关 键 词：胰高血糖素样肽-1 胃肠动力 胃肠动力障碍性疾病 

分 类 号：R57[医药卫生—消化系统]